Table 1

Patient baseline characteristics

CharacteristicsPatients (N=116)
Age
 <65 years, n (%)22 (19.0)
 ≥65 years, n (%)94 (81.0)
 Median (range), years74 (41–93)
Sex, n (%)
 Male81 (69.8)
 Female35 (30.2)
ECOG PS, n (%)
 072 (62.1)
 144 (37.9)
Geographic region, n (%)
 North America29 (25.0)
 Western Europe75 (64.7)
 Australia9 (7.8)
 Asia3 (2.6)
Time since initial diagnosis, median (range), months10.6 (0.7–120.9)
Time since diagnosis of metastatic disease, median (range), months2.2 (0.4–49.6)
Site of primary tumor, n (%)
 Skin104 (89.7)
 Lymph node1 (0.9)
 Not reported11 (9.5)
Visceral metastases at baseline, n (%)
 Present79 (68.1)
 Absent35 (30.2)
 Not reported2 (1.7)
PD-L1 status, n (%)*
 Positive21 (18.1)
 Negative87 (75.0)
 Not evaluable8 (6.9)
MCPyV status, n (%)†
 Positive70 (60.3)
 Negative37 (31.9)
 Not evaluable9 (7.8)
Prior anticancer drug therapy, n (%)
 No110 (94.8)
 Yes6 (5.2)
  • *PD-L1+ status was defined as expression in ≥1% of tumor cells, assessed using a Dako PD-L1 73-10 IHC assay.

  • †Assessed by IHC.

  • ECOG PS, Eastern Cooperative Oncology Group performance status; IHC, immunohistochemistry; MCPyV, Merkel cell polyomavirus; PD-L1, programmed death ligand 1.